A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda
about
Hereditary hemochromatosis in the post-HFE eraAbnormal brain iron metabolism in Irp2 deficient mice is associated with mild neurological and behavioral impairmentsStructural and kinetic characterization of mutant human uroporphyrinogen decarboxylasesSevere radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: a literature reviewA porphodimethene chemical inhibitor of uroporphyrinogen decarboxylaseLike iron in the blood of the people: the requirement for heme trafficking in iron metabolism.Associations among behavior-related susceptibility factors in porphyria cutanea tarda.Hepatitis C, porphyria cutanea tarda and liver iron: an update.Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda.Clinically important features of porphyrin and heme metabolism and the porphyrias.Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relativesMass-spectrometric profiling of porphyrins in complex biological samples with fundamental, toxicological, and pharmacological applications.The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda.Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.Porphyria cutanea tarda associated with HFE C282Y homozygosity, iron overload, and use of a contraceptive vaginal ringDown-regulation of hepcidin in porphyria cutanea tardaReduction of porphyrins to porphyrinogens with palladium on carbon.Precipitating factors of porphyria cutanea tarda in Brazil with emphasis on hemochromatosis gene (HFE) mutations. Study of 60 patientsDiagnosis of common dermopathies in dialysis patients: a review and update.Role of genetic testing in the management of patients with inherited porphyria and their families.Broad spectrum of hepatocyte inclusions in humans, animals, and experimental models.Fragility of epidermis and its consequence in dermatology.Extrahepatic manifestations of hepatitis C virus (HCV).Hepatic porphyria: A narrative review.Porphyria cutanea tarda: an intriguing genetic disease and marker.Uroporphyria in the Cyp1a2-/- mouse.Hepatitis C Treatment in Patients With Porphyria Cutanea Tarda.Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer.Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer.Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
P2860
Q24646056-022EC6CE-5207-4A46-A558-FF93C3778BC9Q27330107-7B61F6CF-BF4A-4C3D-AF65-EB707D7FC158Q27656903-939AEF3D-F650-4F02-8317-8BAD482368C9Q28396407-3E3FBA84-29C8-45EF-B263-C8D889BBDA3BQ28540127-90AAB619-9ED5-49DD-AA02-1180AD58F0A8Q33709768-80C91524-3443-4019-BB44-42279FD11715Q33712331-C7320878-8ADB-4370-A3E0-01EA6746A4D4Q34268811-28B7C909-5111-4790-80E1-DCC37540D213Q34300246-0A4DFF7B-B9AD-48A5-9F17-4B132CB1BE93Q34699532-D9C6B3FC-7FE8-45DE-A621-0A5376FC24FBQ34785744-8C64FBC2-75E6-4454-94FF-D05F5EF8153EQ34979462-C70C541E-E6F5-4CE9-931A-73FC4C6495FDQ35539189-93661AEF-A497-4FA0-84CA-C54F48E1F2E0Q36142859-12D54EE6-2AD8-4DE5-9620-0201FE138FC4Q36267789-F23F199A-3F54-42E5-94F7-C74A0BB25FEEQ36606844-D813C78C-2703-4CE8-997B-D32CD2D2F5E7Q37002005-8FFCFFA7-F470-4C68-AB2C-7754A8DB0702Q37135888-BCCDC001-CAAA-4D1F-98F5-709A34E953E4Q37141723-7CD047ED-D22D-4CA5-9C07-AFCF00C55E04Q38027184-06E61AB3-0B44-4DF6-BC0F-8D6761B4953FQ38100668-2B617ECC-EA3C-455C-BDD5-2D0D14D753E7Q38165139-25E57913-F586-476B-AC7E-B793133615EBQ38220455-DC13CFCD-D7AB-4B9D-807B-B7AB72417357Q38609093-8066BEC4-AA64-48B8-9A76-0C705A6A28F2Q38994896-13E7CF6F-A098-4990-AF9C-67BE434F5A4CQ39189271-312AC2AC-1287-4780-92BF-081039254044Q39345761-214DA8EE-D3B3-4182-9151-570BEF06389CQ39392013-4FA4B483-5D56-4241-8511-24B67A83E46FQ42754591-6F31345D-2895-474D-B322-E518A238D8C8Q51708770-43144D5A-7880-4728-AA4D-53A6B167DA24Q55231652-4BF22059-B669-43DC-B034-57E1DC61A000
P2860
A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@ast
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@en
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@nl
type
label
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@ast
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@en
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@nl
prefLabel
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@ast
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@en
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@nl
P2093
P2860
P3181
P356
P1476
A porphomethene inhibitor of u ...... causes porphyria cutanea tarda
@en
P2093
Christopher A Reilly
Hector A Bergonia
James P Kushner
John D Phillips
Michael R Franklin
P2860
P304
P3181
P356
10.1073/PNAS.0700547104
P407
P577
2007-03-20T00:00:00Z